Early  ||| S:0 E:6 ||| JJ
diagnosis  ||| S:6 E:16 ||| NN
of  ||| S:16 E:19 ||| IN
metastatic  ||| S:19 E:30 ||| JJ
spinal  ||| S:30 E:37 ||| JJ
tumor  ||| S:37 E:43 ||| NN
is  ||| S:43 E:46 ||| VBZ
a  ||| S:46 E:48 ||| DT
key  ||| S:48 E:52 ||| NN
for  ||| S:52 E:56 ||| IN
effective  ||| S:56 E:66 ||| JJ
palliative  ||| S:66 E:77 ||| JJ
radiotherapy  ||| S:77 E:90 ||| NN
in  ||| S:90 E:93 ||| IN
patients  ||| S:93 E:102 ||| NNS
with  ||| S:102 E:107 ||| IN
lung  ||| S:107 E:112 ||| NN
cancer  ||| S:112 E:119 ||| NN
Patients  ||| S:119 E:128 ||| NNS
with  ||| S:128 E:133 ||| IN
metastatic  ||| S:133 E:144 ||| JJ
spinal  ||| S:144 E:151 ||| JJ
tumor  ||| S:151 E:157 ||| NNS
are  ||| S:157 E:161 ||| VBP
the  ||| S:161 E:165 ||| DT
largest  ||| S:165 E:173 ||| JJS
in  ||| S:173 E:176 ||| IN
number  ||| S:176 E:183 ||| NN
among  ||| S:183 E:189 ||| IN
the  ||| S:189 E:193 ||| DT
patients  ||| S:193 E:202 ||| NNS
with  ||| S:202 E:207 ||| IN
bone  ||| S:207 E:212 ||| NN
tumor ||| S:212 E:217 ||| NN
.  ||| S:217 E:219 ||| .
It  ||| S:219 E:222 ||| PRP
causes  ||| S:222 E:229 ||| VBZ
a  ||| S:229 E:231 ||| DT
severe  ||| S:231 E:238 ||| JJ
bone  ||| S:238 E:243 ||| NN
pain ||| S:243 E:247 ||| NN
,  ||| S:247 E:249 ||| ,
pathological  ||| S:249 E:262 ||| JJ
fracture  ||| S:262 E:271 ||| NN
and  ||| S:271 E:275 ||| CC
spinal  ||| S:275 E:282 ||| JJ
cord  ||| S:282 E:287 ||| NN
compression ||| S:287 E:298 ||| NN
.  ||| S:298 E:300 ||| .
Thus  ||| S:300 E:305 ||| RB
it  ||| S:305 E:308 ||| PRP
harshly  ||| S:308 E:316 ||| RB
hampers  ||| S:316 E:324 ||| JJ
patient ||| S:324 E:331 ||| NN
's  ||| S:331 E:334 ||| POS
quality  ||| S:334 E:342 ||| NN
of  ||| S:342 E:345 ||| IN
life ||| S:345 E:349 ||| NN
.  ||| S:349 E:351 ||| .
We  ||| S:351 E:354 ||| PRP
report  ||| S:354 E:361 ||| VBP
3  ||| S:361 E:363 ||| CD
patients  ||| S:363 E:372 ||| NNS
with  ||| S:372 E:377 ||| IN
lung  ||| S:377 E:382 ||| NN
cancer  ||| S:382 E:389 ||| NN
whose  ||| S:389 E:395 ||| WP$
initial  ||| S:395 E:403 ||| JJ
manifestation  ||| S:403 E:417 ||| NN
was  ||| S:417 E:421 ||| VBD
metastatic  ||| S:421 E:432 ||| JJ
spinal  ||| S:432 E:439 ||| JJ
tumor ||| S:439 E:444 ||| NN
.  ||| S:444 E:446 ||| .
We  ||| S:446 E:449 ||| PRP
treated  ||| S:449 E:457 ||| VBD
the  ||| S:457 E:461 ||| DT
3  ||| S:461 E:463 ||| CD
patients  ||| S:463 E:472 ||| NNS
with  ||| S:472 E:477 ||| IN
palliative  ||| S:477 E:488 ||| JJ
radiotherapy  ||| S:488 E:501 ||| NN
and  ||| S:501 E:505 ||| CC
medication ||| S:505 E:515 ||| NN
.  ||| S:515 E:517 ||| .
Although  ||| S:517 E:526 ||| IN
the  ||| S:526 E:530 ||| DT
severe  ||| S:530 E:537 ||| JJ
pain  ||| S:537 E:542 ||| NN
has  ||| S:542 E:546 ||| VBZ
improved  ||| S:546 E:555 ||| VBN
on  ||| S:555 E:558 ||| IN
a  ||| S:558 E:560 ||| DT
numerical  ||| S:560 E:570 ||| JJ
rating  ||| S:570 E:577 ||| NN
scale ||| S:577 E:582 ||| NN
( ||| S:582 E:583 ||| -LRB-
NRS ||| S:583 E:586 ||| NNP
) ||| S:586 E:587 ||| -RRB-
,  ||| S:587 E:589 ||| ,
but  ||| S:589 E:593 ||| CC
performance  ||| S:593 E:605 ||| NN
status ||| S:605 E:611 ||| NN
( ||| S:611 E:612 ||| -LRB-
PS ||| S:612 E:614 ||| NNP
) ||| S:614 E:615 ||| -RRB-
and  ||| S:615 E:619 ||| CC
activity  ||| S:619 E:628 ||| NN
of  ||| S:628 E:631 ||| IN
daily  ||| S:631 E:637 ||| JJ
living ||| S:637 E:643 ||| NN
( ||| S:643 E:644 ||| -LRB-
ADL ||| S:644 E:647 ||| NNP
) ||| S:647 E:648 ||| -RRB-
of  ||| S:648 E:651 ||| IN
the  ||| S:651 E:655 ||| DT
3  ||| S:655 E:657 ||| CD
patients  ||| S:657 E:666 ||| NNS
got  ||| S:666 E:670 ||| VBD
worse  ||| S:670 E:676 ||| JJR
because  ||| S:676 E:684 ||| IN
the  ||| S:684 E:688 ||| DT
disease  ||| S:688 E:696 ||| NN
was  ||| S:696 E:700 ||| VBD
progressed  ||| S:700 E:711 ||| VBN
and  ||| S:711 E:715 ||| CC
complicated ||| S:715 E:726 ||| JJ
.  ||| S:726 E:728 ||| .
Generally ||| S:728 E:737 ||| RB
,  ||| S:737 E:739 ||| ,
PS  ||| S:739 E:742 ||| NNP
of  ||| S:742 E:745 ||| IN
cancer  ||| S:745 E:752 ||| NN
patients  ||| S:752 E:761 ||| NNS
found  ||| S:761 E:767 ||| VBD
by  ||| S:767 E:770 ||| IN
bone  ||| S:770 E:775 ||| NN
matastasis  ||| S:775 E:786 ||| NN
is  ||| S:786 E:789 ||| VBZ
low ||| S:789 E:792 ||| JJ
.  ||| S:792 E:794 ||| .
However ||| S:794 E:801 ||| RB
,  ||| S:801 E:803 ||| ,
it  ||| S:803 E:806 ||| PRP
is  ||| S:806 E:809 ||| VBZ
difficult  ||| S:809 E:819 ||| JJ
to  ||| S:819 E:822 ||| TO
take  ||| S:822 E:827 ||| VB
an  ||| S:827 E:830 ||| DT
effective  ||| S:830 E:840 ||| JJ
treatment ||| S:840 E:849 ||| NN
,  ||| S:849 E:851 ||| ,
which  ||| S:851 E:857 ||| WDT
leads  ||| S:857 E:863 ||| VBZ
to  ||| S:863 E:866 ||| TO
ADL  ||| S:866 E:870 ||| NNP
improvement ||| S:870 E:881 ||| NN
.  ||| S:881 E:883 ||| .
There  ||| S:883 E:889 ||| EX
are  ||| S:889 E:893 ||| VBP
many  ||| S:893 E:898 ||| JJ
choices  ||| S:898 E:906 ||| NNS
for  ||| S:906 E:910 ||| IN
treating  ||| S:910 E:919 ||| VBG
metastatic  ||| S:919 E:930 ||| JJ
bone  ||| S:930 E:935 ||| NN
tumors  ||| S:935 E:942 ||| NNS
including  ||| S:942 E:952 ||| VBG
pain  ||| S:952 E:957 ||| NN
control ||| S:957 E:964 ||| NN
,  ||| S:964 E:966 ||| ,
bisphosphonate  ||| S:966 E:981 ||| JJ
administration ||| S:981 E:995 ||| NN
,  ||| S:995 E:997 ||| ,
radiation  ||| S:997 E:1007 ||| NN
therapy ||| S:1007 E:1014 ||| NN
,  ||| S:1014 E:1016 ||| ,
strontium  ||| S:1016 E:1026 ||| JJ
radiotherapy ||| S:1026 E:1038 ||| NN
,  ||| S:1038 E:1040 ||| ,
bone  ||| S:1040 E:1045 ||| NN
cement ||| S:1045 E:1051 ||| NN
,  ||| S:1051 E:1053 ||| ,
palliative  ||| S:1053 E:1064 ||| JJ
surgery  ||| S:1064 E:1072 ||| NN
and  ||| S:1072 E:1076 ||| CC
orthotics ||| S:1076 E:1085 ||| NN
.  ||| S:1085 E:1087 ||| .
In  ||| S:1087 E:1090 ||| IN
addition ||| S:1090 E:1098 ||| NN
,  ||| S:1098 E:1100 ||| ,
a  ||| S:1100 E:1102 ||| DT
development  ||| S:1102 E:1114 ||| NN
of  ||| S:1114 E:1117 ||| IN
molecular  ||| S:1117 E:1127 ||| JJ
target  ||| S:1127 E:1134 ||| NN
drugs ||| S:1134 E:1139 ||| NNS
,  ||| S:1139 E:1141 ||| ,
such  ||| S:1141 E:1146 ||| JJ
as  ||| S:1146 E:1149 ||| IN
Denosmab ||| S:1149 E:1157 ||| NNP
,  ||| S:1157 E:1159 ||| ,
is  ||| S:1159 E:1162 ||| VBZ
expected  ||| S:1162 E:1171 ||| VBN
as  ||| S:1171 E:1174 ||| IN
future  ||| S:1174 E:1181 ||| JJ
modality  ||| S:1181 E:1190 ||| NN
of  ||| S:1190 E:1193 ||| IN
palliative  ||| S:1193 E:1204 ||| JJ
care ||| S:1204 E:1208 ||| NN
.  ||| S:1208 E:1210 ||| .
In  ||| S:1210 E:1213 ||| IN
conclusion ||| S:1213 E:1223 ||| NN
,  ||| S:1223 E:1225 ||| ,
we  ||| S:1225 E:1228 ||| PRP
should  ||| S:1228 E:1235 ||| MD
detect  ||| S:1235 E:1242 ||| VB
a  ||| S:1242 E:1244 ||| DT
bone  ||| S:1244 E:1249 ||| NN
metastasis  ||| S:1249 E:1260 ||| NN
in  ||| S:1260 E:1263 ||| IN
the  ||| S:1263 E:1267 ||| DT
patient  ||| S:1267 E:1275 ||| NN
with  ||| S:1275 E:1280 ||| IN
lung  ||| S:1280 E:1285 ||| NN
cancer  ||| S:1285 E:1292 ||| NN
as  ||| S:1292 E:1295 ||| IN
early  ||| S:1295 E:1301 ||| JJ
as  ||| S:1301 E:1304 ||| IN
possible ||| S:1304 E:1312 ||| JJ
,  ||| S:1312 E:1314 ||| ,
and  ||| S:1314 E:1318 ||| CC
select  ||| S:1318 E:1325 ||| VB
an  ||| S:1325 E:1328 ||| DT
appropriate  ||| S:1328 E:1340 ||| JJ
treatment  ||| S:1340 E:1350 ||| NN
in  ||| S:1350 E:1353 ||| IN
collaboration  ||| S:1353 E:1367 ||| NN
with  ||| S:1367 E:1372 ||| IN
each  ||| S:1372 E:1377 ||| DT
specialist  ||| S:1377 E:1388 ||| NN
for  ||| S:1388 E:1392 ||| IN
achieving  ||| S:1392 E:1402 ||| VBG
the  ||| S:1402 E:1406 ||| DT
ADL  ||| S:1406 E:1410 ||| NNP
and  ||| S:1410 E:1414 ||| CC
PS  ||| S:1414 E:1417 ||| NNP
improvement ||| S:1417 E:1428 ||| NN
.  ||| S:1428 E:1430 ||| .
